Tardive Dyskinesia

1992 ◽  
Vol 160 (1) ◽  
pp. 110-112 ◽  
Author(s):  
Robertson Macpherson ◽  
Rachel Collis
Keyword(s):  
Cognitive Function ◽  
Tardive Dyskinesia ◽  
Psychiatric Hospital ◽  
Negative Symptoms ◽  
Cognitive Deficit ◽  
Defect State ◽  
Abnormal Involuntary Movements ◽  
Involuntary Movements ◽  
Short Test

Of 113 patients in long-stay wards of a psychiatric hospital, 43 had TD. Twenty-six of the 39 patients who consented to take part in the study were unaware of abnormal involuntary movements. These patients scored significantly lower on a short test of cognitive function than patients who were aware of such movements. The diagnosis of schizophrenia, perticularly the ‘defect’ state with cognitive deficit and negative symptoms, was found to be associated with lack of awareness of TD.

The Nithsdale Schizophrenia Survey V. Follow-up of Tardive Dyskinesia at3-1/2 years

1986 ◽  
Vol 149 (5) ◽  
pp. 621-623 ◽  
Author(s):  
A. D. T. Robinson ◽  
R. G. McCreadie
Keyword(s):  
Tardive Dyskinesia ◽  
Older Patients ◽  
Geographical Area ◽  
Point Prevalence ◽  
Abnormal Involuntary Movements ◽  
Involuntary Movements ◽  
Transient Feature

The point-prevalence of tardive dyskinesia in schizophrenics from a discrete geographical area (Nithsdale, in Dumfries and Galloway Region) in 1981, 1982, and 1984 was 31%, 27%, and 30% respectively. This suggests that the prevalence of tardive dyskinesia in a community of schizophrenics has reached a plateau. In 12% of patients there was persistent dyskinesia, i.e. abnormal involuntary movements were present at all three assessments. Persistent dyskinesia was more common in older patients. The severity of tardive dyskinesia fluctuated between assessments in 41 % of patients, indicating that it is only a transient feature in some cases.

Late Onset Involuntary Movements in Chronic Schizophrenia: Relationship of ‘Tardive’ Dyskinesia to Intellectual Impairment and Negative Symptoms

1986 ◽  
Vol 149 (5) ◽  
pp. 616-620 ◽  
Author(s):  
J. L. Waddington ◽  
H. A. Youssef
Keyword(s):  
Tardive Dyskinesia ◽  
Negative Symptoms ◽  
Late Onset ◽  
Chronic Schizophrenia ◽  
Intellectual Impairment ◽  
Medication History ◽  
Involuntary Movements ◽  
Schizophrenic Patients ◽  
Relationship Of

Intellectual impairment, negative symptoms, and medication history were assessed in chronic schizophrenic patients with and without abnormal involuntary movements (tardive dyskinesia). Patients with involuntary movements had received neither longer nor more intensive treatment with neuroleptics or anticholinergics. However, the presence or absence of involuntary movements was prominently associated with the presence or absence of intellectual impairment/negative symptoms; these features are characteristic of the defect state/type II syndrome of schizophrenia, in which structural abnormalities of the brain may be over-represented. The role of subtle organic changes in conferring vulnerability to the emergence of such involuntary movements should be re-evaluated.

Treatment of Tardive Dyskinesia with Dihydrogenated Ergot Alkaloids (Hydergine) a Pilot Study

1980 ◽  
Vol 25 (4) ◽  
pp. 325-328 ◽  
Author(s):  
S.N. Mohamed ◽  
S. Kazarian ◽  
H. Merskey ◽  
M.G.G. Thompson
Keyword(s):  
Pilot Study ◽  
Tardive Dyskinesia ◽  
Ergot Alkaloids ◽  
Abnormal Involuntary Movements ◽  
Sustained Improvement ◽  
Involuntary Movements ◽  
Treatment Improvement

Five patients with abnormal involuntary movements of tardive dyskinesia were treated with dihydrogenated ergot alkaloids (Hydergine) in doses of 3 to 4 milligrams a day for six weeks. Blind ratings of standard videotape recordings indicated significant differences between the patients. Worsening occurred in three patients during treatment and to a lesser extent after treatment; improvement during treatment appeared in one patient and more sustained improvement in one patient.

scholarly journals Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study

2021 ◽  
pp. 107839032110235
Author(s):  
Andrew J. Cutler ◽  
Stanley N. Caroff ◽  
Caroline M. Tanner ◽  
Huda Shalhoub ◽  
William R. Lenderking ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Real World ◽  
Treatment Options ◽  
Body Region ◽  
Full Time ◽  
Abnormal Involuntary Movements ◽  
Involuntary Movements ◽  
Screening Study ◽  
Part Time ◽  
The Impact

Background: RE-KINECT (NCT03062033), a real-world study of possible tardive dyskinesia (TD) in antipsychotic-treated patients, included a questionnaire to assess the effects of patients’ abnormal involuntary movements on caregivers. Objective: To capture the experiences of caregivers who assisted individuals with abnormal involuntary movements that were confirmed by clinicians as being consistent with TD. Methods: Qualified (nonpaid) caregivers were invited to complete a questionnaire that included the following: caregivers’ sociodemographic characteristics, their perceptions about the impact of abnormal involuntary movements on patients, and the impact of these movements on themselves (caregivers). Results: Of the 41 participating caregivers, 25 (61.0%) were women, 20 (48.8%) were employed full time or part time, and 35 (85.4%) were family members or friends. Based on responses from caregivers who noticed patients’ abnormal involuntary movements and were caring for individuals who also noticed those movements, 48.0% of patients had “a lot” of severity in ≥1 body region and 76.0% had abnormal involuntary movements in ≥2 regions. Caregiver ratings were significantly correlated with patient ratings (but not with clinician ratings) for maximum severity of abnormal involuntary movements and the number of affected regions (both p <.05). Based on their own judgments and perceptions, caregivers reported that the patient’s movements had “some” or “a lot” of impact on their (caregiver’s) ability to continue usual activities (50.0%), be productive (58.3%), socialize (55.6%), or take care of self (50.0%). Conclusion: Caregivers as well as patients are negatively affected by TD, and the impact of TD on caregivers’ lives should be considered when determining treatment options.

Tardive dyskinesia and deficit schizophrenia

2011 ◽  
Vol 26 (S2) ◽  
pp. 1514-1514
Author(s):  
S. Telfer ◽  
S. Shivashankar ◽  
R. McCreadie ◽  
B. Kirkpatrick
Keyword(s):  
Tardive Dyskinesia ◽  
Negative Symptoms ◽  
Rating Scale ◽  
Pathological Process ◽  
Involuntary Movements ◽  
Deficit Syndrome ◽  
Deficit Schizophrenia ◽  
The People ◽  
Key Informant ◽  
Patients Experience

IntroductionDespite comparable antipsychotic exposure, some patients experience involuntary movements yet others do not. Negative symptoms have been associated with tardive dyskinesia, but it is not certain that this is an association with primary negative symptoms.AimsTo determine whether patients with deficit schizophrenia (who have primary negative symptoms) are more likely to experience tardive dyskinesia than those with non-deficit schizophrenia.MethodsIn 2006 all the people with a clinical diagnosis of schizophrenia in Nithsdale, South West Scotland, were identified using the ‘key informant’ method. These patients were assessed using the Schedule for the Deficit Syndrome (SDS) and for the presence of dyskinesia using the Abnormal Involuntary Movements Scale (AIMS). Patients were also assessed for akathisia using the Barnes-Akathisia Scale and for extrapyramidal side effects using the Simpson and Angus rating scale.ResultsThere is a significant association between deficit and TD when controlling for age. Those with tardive dyskinesia are more likely to have deficit schizophrenia. The odds ratio is 3.08 (95% CI 1.28, 7.37), p = 0.012.ConclusionsOur findings support the proposal that the pathological process underlying deficit schizophrenia can predispose to the development of tardive dyskinesia.

scholarly journals Interaction of clozapine with metformin in a schizophrenia rat model

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
G. Horvath ◽  
G. Kis ◽  
G. Kekesi ◽  
A. Büki ◽  
L. G. Adlan ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cognitive Function ◽  
Negative Symptoms ◽  
Antipsychotic Drugs ◽  
D1 Receptor ◽  
Antidiabetic Drug ◽  
Beneficial Effects ◽  
Adjuvant Therapies ◽  
Behavioral Parameters ◽  
The Brain

AbstractThe low efficacy of antipsychotic drugs (e.g., clozapine) for negative symptoms and cognitive impairment has led to the introduction of adjuvant therapies. Because previous data suggest the procognitive potential of the antidiabetic drug metformin, this study aimed to assess the effects of chronic clozapine and metformin oral administration (alone and in combination) on locomotor and exploratory activities and cognitive function in a reward-based test in control and a schizophrenia-like animal model (Wisket rats). As impaired dopamine D1 receptor (D1R) function might play a role in the cognitive dysfunctions observed in patients with schizophrenia, the second goal of this study was to determine the brain-region-specific D1R-mediated signaling, ligand binding, and mRNA expression. None of the treatments affected the behavior of the control animals significantly; however, the combination treatment enhanced D1R binding and activation in the cerebral cortex. The Wisket rats exhibited impaired motivation, attention, and cognitive function, as well as a lower level of cortical D1R binding, signaling, and gene expression. Clozapine caused further deterioration of the behavioral parameters, without a significant effect on the D1R system. Metformin blunted the clozapine-induced impairments, and, similarly to that observed in the control animals, increased the functional activity of D1R. This study highlights the beneficial effects of metformin (at the behavioral and cellular levels) in blunting clozapine-induced adverse effects.

scholarly journals Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats

Gene Therapy ◽  
2021 ◽  
Author(s):  
Goichi Beck ◽  
Jie Zhang ◽  
Kayoko Fong ◽  
Hideki Mochizuki ◽  
M. Maral Mouradian ◽  
...  
Keyword(s):  
Gene Suppression ◽  
Abnormal Involuntary Movements ◽  
Involuntary Movements

Sub-syndromes of tardive dyskinesia and some clinical correlates

1992 ◽  
Vol 22 (4) ◽  
pp. 923-927 ◽  
Author(s):  
K. W. Brown ◽  
T. White
Keyword(s):  
Cognitive Impairment ◽  
Tardive Dyskinesia ◽  
Movement Disorder ◽  
Principal Components Analysis ◽  
Principal Components ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Clinical Correlates ◽  
Facial Movements ◽  
Components Analysis

SynopsisSyndromes of dyskinetic movements in subjects (N = 70) with chronic schizophrenia were investigated, using principal components analysis of AIMS ratings. Consonant with previous research, three discrete groupings were found, namely dyskinetic movements of lips-jaw-tongue, limb-truncal and facial movements. These were then related to demographic, psychological and movement disorder variables. The limb-truncal, but neither the lips-jaw-tongue nor facial movements components, were associated with negative symptoms and cognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document